指南与共识MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗白血病

异基因造血干细胞移植在「非经典型」骨髓增殖性肿瘤及骨髓增生异常/骨髓增殖性肿瘤中的作用:EBMT实践协调与指南委员会及慢性恶性肿瘤工作组的推荐

Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT.
指南 / 共识 · Blood · 2025-01-01

欧洲血液与骨髓移植学会(EBMT)实践协调与指南委员会及慢性恶性肿瘤工作组联合制定指南,基于2016年修订第四版世界卫生组织分类以来的文献综述与多轮专家讨论,针对「非经典型」骨髓增殖性肿瘤及骨髓增生异常/骨髓增殖性肿瘤的异基因造血干细胞移植选择与管理提出推荐。

要点

  • 应早期识别潜在移植候选者,尤其见于慢性中性粒细胞白血病、慢性嗜酸性粒细胞白血病/CEL-NOS等类型。
  • 伴FGFR1、JAK2、ABL1、FLT3重排的髓系/淋系肿瘤伴嗜酸性粒细胞增多及酪氨酸激酶基因融合者需早期识别移植候选。
  • MPN-NOS/MPN不能分类者按骨髓纤维化标准推荐,MDS/MPN伴血小板增多者按MDS指南推荐移植。

核心结论

  • 针对「非经典型」骨髓增殖性肿瘤及骨髓增生异常/骨髓增殖性肿瘤缺乏标准化管理方案,本指南旨在优化此类罕见肿瘤患者的移植选择与管理。
  • 鉴于当前缺乏有力证据,本文档将作为指导未来研究活动的资源,为解答关键未决问题提供框架。

研究设计与样本

  • 由欧洲血液与骨髓移植学会(EBMT)实践协调与指南委员会与慢性恶性肿瘤工作组合作制定。
  • 对2016年修订第四版世界卫生组织分类发布以来的文献进行了全面综述。
  • 多学科专家组通过多轮草案传阅形成本文件。

主要发现

  • 关键推荐包括早期识别潜在移植候选者,尤其见于慢性中性粒细胞白血病、慢性嗜酸性粒细胞白血病(CEL)/CEL-NOS、伴FGFR1、JAK2、ABL1和FLT3重排的髓系/淋系肿瘤伴嗜酸性粒细胞增多及酪氨酸激酶基因融合、MDS/MPN伴中性粒细胞增多/非典型慢性髓性白血病及MDS/MPN-NOS。
  • 对MPN-NOS/MPN不能分类患者,应应用骨髓纤维化的标准推荐。
  • 对MDS/MPN伴血小板增多患者,基于已建立的MDS指南推荐移植。

关键数值与推荐

  • 早期识别潜在移植候选者推荐适用于慢性中性粒细胞白血病、CEL/CEL-NOS、伴FGFR1、JAK2、ABL1和FLT3重排的髓系/淋系肿瘤伴嗜酸性粒细胞增多及酪氨酸激酶基因融合、MDS/MPN伴中性粒细胞增多/非典型慢性髓性白血病及MDS/MPN-NOS。
  • MPN-NOS/MPN不能分类者应用骨髓纤维化的标准推荐。
  • MDS/MPN伴血小板增多者基于已建立的MDS指南推荐移植。

临床怎么用

  • 对慢性中性粒细胞白血病、CEL/CEL-NOS、伴FGFR1、JAK2、ABL1和FLT3重排的髓系/淋系肿瘤伴嗜酸性粒细胞增多及酪氨酸激酶基因融合、MDS/MPN伴中性粒细胞增多/非典型慢性髓性白血病及MDS/MPN-NOS患者,应早期识别潜在移植候选者。
  • 对MPN-NOS/MPN不能分类患者,按骨髓纤维化的标准推荐管理。
  • 对MDS/MPN伴血小板增多患者,按已建立的MDS指南推荐移植。

局限性

  • 原文指出当前缺乏有力证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

"Nonclassical" myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) represent a heterogeneous group of malignancies characterized by a wide range of clinical manifestations. Unlike classical MPNs, there is no standardized management approach for these conditions, particularly concerning the indications for and management of allogeneic hematopoietic cell transplantation. To address this gap, the European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonization and Guidelines (PH&G) Committee and the Chronic Malignancies Working Party (CMWP) have collaborated to develop shared guidelines aimed at optimizing the selection and management of patients with these rare forms of neoplasms. A comprehensive review of the literature from the publication of the revised fourth edition of the (2016) World Health Organization classification onward was conducted. A multidisciplinary group of experts in the field convened to produce this document, which was developed through multiple rounds of draft circulation. Key recommendations include the early identification of potential transplant candidates, particularly in cases of chronic neutrophilic leukemia, chronic eosinophilic leukemia (CEL)/CEL, not otherwise specified (CEL-NOS), myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions with FGFR1, JAK2, ABL1, and FLT3 rearrangements, MDS/MPN with neutrophilia/atypical chronic myeloid leukemia, and MDS/MPN, NOS. For patients with MPN, NOS/MPN unclassifiable, standard recommendations for myelofibrosis should be applied. Similarly, in MDS/MPN with thrombocytosis, transplantation is recommended on the basis of established MDS guidelines. Given the current lack of robust evidence, this document will serve as a valuable resource to guide future research activities, providing a framework for addressing critical unanswered questions and advancing the field.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Polverelli N, Hernández-Boluda JC, Onida F, et al. Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT. Blood. 2025. PMID: 40106773. doi:10.1182/blood.2024028000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。